B.B. was supported by the Defense Congressionally Directed Medical Research Program (No. W81XWH-22-1-0208), and reports institutional research funding from Amgen Inc, Artios Pharma, Boehringer Ingelheim, Bicycle Therapeutics, Daiichi Sankyo, KAHR Medical, Lyell Immunopharma, Merck, Pionyr Immunotherapeutics, RASCAL Therapeutics, Syros Pharmaceuticals, Tarveda Therapeutics, all outside the submitted work. A.C.M. was supported by funding from the Radiological Society of North America and the ViewRay Co.

Conception and design: Babar Bashir

Data analysis and interpretation: Adam C. Mueller

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Pancreatic Adenocarcinoma: An Evolving yet Unimpressive Treatment Landscape

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Babar Bashir

Research Funding: Boehringer Ingelheim (Inst), Ikena Oncology (Inst), Bicycle Therapeutics (Inst), Syros Pharmaceuticals (Inst), KAHR Medical (Inst), Tarveda Therapeutics (Inst), Amgen (Inst), RasCal (Inst), Merck (Inst), Artios (Inst), Daiichi Sankyo/Lilly (Inst), Pionyr (Inst), Lyell Immunopharma (Inst)

Adam C. Mueller

Research Funding: ViewRay (Inst)

No other potential conflicts of interest were reported.